Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biostem Technologies Inc (OP:BSEM)

4.637 UNCHANGED
Streaming Delayed Price Updated: 3:15 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biostem Technologies Inc

BioStem Technologies Innovative Wound-Care Treatments Steepen Its Growth Trajectory ($BSEM)
Via AB Newswire
BioStem Technologies Inc. In A Race To The Top With Innovative Wound-Care Treatments ($BSEM)
Via AB Newswire
Topics Intellectual Property
BioStem Technologies Announces Opening of First Clinical Site for Diabetic Foot Ulcer Study
Via ACCESSWIRE
BioStem Technologies to Highlight Core Advanced Wound Care Portfolio at SAWC Fall 2023 Conference
Via ACCESSWIRE
BioStem Technologies: CMS Decision a “Win For Patients”
Via ACCESSWIRE
BioStem Receives IRB Approval for Clinical Study to Evaluate Vendaje(R) in Diabetic Foot Ulcers
Via ACCESSWIRE
BioStem Technologies Initiates Nationwide Launch of AmnioWrap2(TM) with Venture Medical
Via ACCESSWIRE
BioStem Technologies Engages PCG Advisory for Strategic Investor Relations
Via ACCESSWIRE
NovaBay Pharmaceuticals Announces Agreement with BioStem Technologies to Commercialize Amniotic Tissue Allograft as Avenova® Allograft
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
How BioStem Plans To Grow Its Perinatal Allografts In 2023 – And Beyond
Florida-based BioStem Technologies, Inc. (OTCMKTS: BSEM) is a biotech company focused on developing and manufacturing structural-tissue allografts derived from perinatal tissues and intended for use as... 
Via Benzinga
2022 Year in Review: BioStem Technologies Looks Back At A Year of Growth And Expansion
BioStem Technologies, Inc. (OTCQB: BSEM) is a Florida-based biotechnology company focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization... 
Via Benzinga
BioStem Technologies Announces Partnership with Kill Cliff FC
From BioStem Technologies, Inc.
Via GlobeNewswire
BioStem Technologies Reports Third Quarter 2022 Operating and Financial Results
From BioStem Technologies, Inc.
Via GlobeNewswire
BioStem Technologies to Host Third Quarter Financial Results and Corporate Update Conference Call
From BioStem Technologies, Inc.
Via GlobeNewswire
BioStem Promotes Michael Fortunato, CPA to Chief Financial Officer
From BioStem Technologies, Inc.
Via GlobeNewswire
BioStem to Present at the Dawson James Securities 2022 Small Cap Growth Conference
From BioStem Technologies, Inc.
Via GlobeNewswire
BioStem Technologies (OTCMKTS: BSEM) Coverage Initiated at Zacks Investment Research
The below report was authored by Brad Sorensen, CFA, Zacks Small Cap Research. You can find the original report here.   
Via Benzinga
EXCLUSIVE: BioStem Technologies Reports Q1 Net Revenue Up 211% YoY
BioStem Technologies Inc. (OTC: BSEM), a regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics today, reported financial results... 
Via Benzinga
Cannabis Movers & Shakers: Halo Collective, Suite 420 Access, OWP, BioStem, Chicago Atlantic Advisors, Silo Wellness
Halo Collective Taps Have a Heart's CEO Ryan Kunkel Halo Collective Inc. (NEO:HALO)(OTCQX: 
Via Benzinga
Topics Cannabis
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.